Bob Doody returns to lead IR at Idera Pharmaceuticals

Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, has appointed award-winning IRO Bob Doody as its new vice president of IR and corporate communications.

Prior to joining Idera, Doody served for eight years at ViroPharma – where he also led the IR team for five years – before the company was taken over by Shire Pharmaceuticals in January 2014.

During his time at ViroPharma, the company ‘transformed to be a leading developer of innovative therapies for rare diseases, highlighted by its lead product, Cinryze, for the treatment of hereditary angioedema in the US and Europe,’ notes an Idera press release. After the takeover, Doody also worked as part of Shire Pharmaceuticals’ integration team.

On an IR note, Doody helped ViroPharma take home two IR Magazine Awards before it became part of Shire Pharmaceuticals. As well as the 2013 grand prix for best overall investor relations (small cap), Doody and his colleague shared the best investor relations professional (small cap) accolade.

Before moving into IR, the communications graduate spent several years at healthcare communications firm Dorland Sweeney Jones in Philadelphia as well as serving in the United States Navy.

‘I am thrilled to have the opportunity to work with Bob again,’ says Vincent Milano, CEO of Idera Pharmaceuticals, in a statement welcoming Doody to the company. ‘Bob has tremendous credibility with investors and has earned their confidence as a world-class IR professional. In addition, his passion and energy fit well with [Idera’s] people and our needs.’

‘I’m very excited to be joining Idera and continuing the strong working relationship I have with Vin Milano from our days at ViroPharma,’ says Doody. ‘Historically, Idera has not really had a consistent, strategic IR effort. My immediate goals are to implement a core IR program and begin to establish the level of transparency and value for the Wall Street community with Idera that those in that community came to expect from ViroPharma.’